Congressional committees have advanced initial measures to address prescription drug costs. However, their work to date has not focused on the significant policy changes needed to meaningfully lower drug prices. To address the drivers of excessive prescription drug prices in the United States, the Coalition for Fair Drug Prices urges Congress to enact meaningful policies that leverage the federal government’s power to negotiate drug prices.
In state houses all across the country, advocates, legislators, and state officials are considering proposals to restore the Affordable Care Act’s (ACA’s) temporary reinsurance program, which ended after 2016. This “Reinsurance 101” issue brief describes reinsurance and explains why it was originally included in the ACA. It then analyzes why some advocates and policymakers might consider implementing reinsurance in their states but others could hesitate to pursue such a policy.
High and rising drug prices jeopardize consumers’ health and well-being.1 To address the harms of high drug prices, families across America want and deserve meaningful reforms that target and reduce the underlying “list” prices of drugs. Polling shows that nine out of 10 voters support allowing the government to negotiate lower drug prices in Medicare.2
An increasing number of states are making harmful changes to their Medicaid programs using “Section 1115 waivers.” Families USA is tracking state Medicaid waivers that restrict access to quality, affordable health care for low-income families and adults. This new grid offers an overview of the status of each state’s waiver proposal, the restrictive elements of the waiver proposal, and CMS’s decision on each element.
Anyone with compassion for others will find the anti-abortion efforts and rhetoric underway in Alabama and other states disgraceful. Having a woman walk into a health clinic or doctor’s office and not being able to receive the care she needs or being able to make her own reproductive choices is profoundly wrong, problematic and a huge step in the wrong direction for the future of health care.
One of the strangest chapters in the Affordable Care Act’s history began a few hours after midnight on October 13, 2017. At 2:36 am, a Presidential tweet announced the end of cost-sharing-reduction (CSR) payments to insurers: “The Democrats [sic] ObamaCare is imploding. Massive subsidy payments to their pet insurance companies has [sic] stopped. Dems should call me to fix!” Later that morning, officials at the Department of Health and Human Services explained that the federal government would soon stop reimbursing insurers to cover the cost of giving low-income consumers legally-required reductions in out-of-pocket cost-sharing.
This summary outlines significant policies that advanced in 2019 addressing prescription drug prices in states all over the country. Advocates and lawmakers can gain a sense of what has been made possible this legislative session, and gain insight into what could come next to tackle high drug prices.
This guide outlines model policies for states to consider to rein in drug prices in 2019 and beyond. Those discussed first most directly target drug prices and therefore are likely to have the greatest impact. This piece also cautions against prioritizing approaches to import drugs from Canada, as these policies are less likely to bring savings despite their public appeal.
This analysis summarizes the SPA approval process and identifies where delays in the process might occur.
This fact sheet provides advocates and policymakers a step-by-step overview comparing the approval process and timeline to get a SPA vs. Medicaid 1115 Waiver approved.